High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...
China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should invest ...
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...
Vir Biotechnology ( (VIR)) has provided an update. On January 12, 2026, Vir Biotechnology reported updated positive Phase 2 SOLSTICE data in chronic hepatitis delta showing that combination therapy ...
Potential breakthrough therapeutic for estimated $50+ billion global immunotherapy market; first and only telomere-targeting anticancer agent in clinical development anywhere CHICAGO, Jan. 20, 2026 ...
CHICAGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results